Monthly Archives: February 2021

Jack Perry|The Providence Journal

Anticipating winter storms so he can keep Rhode Island highways plowed, the state Department of Transportation'sJoe Bucci can talk to forecasters, watch radar and monitor systems that tell him road temperatures across the state.

But he doesn't overlook his own senses, sharpened by a career spent plowing through storms dating back to the Blizzard of '78. Sometimes the size of the snowflakes, the smell of the air can tell him as much about a storm as a computer model might.

"I don't make forecasts. I don't consider myself a weatherman, but you kind of get a feel for it," Bucci says.

Astate highway operations engineer, Bucci is in charge of the DOT's Division of Highway and Bridge Maintenance. After a slow start to the winter, Buccihas been busy lately as a series of storms have moved through the region.

He's a key player in ensuring the state's 3,300 miles of highway lane miles are treated and plowed. Bucci has to know when and where the state should deploy its fleet of 178 trucks, and when, or if, to call private vendors who can provide another350 trucks.

"We have to be prepared for the worst," Bucci says.

Still, it's a delicatebalance. Underplay the threat, and the roads are a mess; travel is hazardous. Put the trucks on the road too early, the budget gets blown, and the drivers might be out there too long, exhausted.

"Unfortunately, there's really no secret sauce," Bucci says.

Bucci has a wealth of technology and information at his disposal. AccuWeather provides the DOT 24-hour access to a forecaster. Bucci can pull plenty of information from the National Weather Service's website andsit in on their storm discussions.

The DOT also uses a weather station that provides real-time information on factors such as air temperature, road temperature and wind speed in various parts of the state.

"We take all of these things, pour it into a big pot and stir it," Bucci says.

More: Snow should start this morning, continue into Friday; 4 to 6 inches likely

More: So far January has been warm, but will it stay that way, and could it mean snow for Rhode Island?

More: Storm watch issued for Sunday; get used to it, AccuWeather says

Knowing when the storm will start is one of the most important pieces of information, but it's not always clear. Computer models and forecasters don't always agree. "The timing is very important for us, especially if it's going to affect the morning or evening commute," Buccisays.

The intensity of the storm is also key. If the snow falls at a rate greater than 1 inch an hour, it's tough for the plows to keep up.

"We do everything we can to keep the roads as safe as possible," he says.

Here's something that adds to the challenge: The weather in Rhode Island can vary dramatically across just a few miles. Oftentimes, when it's snowing inBurrillville, it's raining in Newport. Or it might be snowing along the coast, but dry in the northern part of the state. "As small as we are, believe it or not, we have several different microclimates," Bucci says.

That's where experience helps again. The state has seven different highway districts, and staff membersin those districtshave a good feel for when and where problems are likely to surface, Bucci says.

Once astorm starts, DOT supervisors can monitor conditions and progress of the plow crews from a warm office. The state has several cameras set on roads and bridges. The trucks have GPS systems that send information on location. Many of the trucks also have cameras that can relay conditions back to headquarters. Some even have monitors that indicate whether too much or too little treatment is being put on the road surface.

In pre-COVID days, several DOT employees could gather in the "storm room" to keep an eye on developments, but now they haveto keep farther apart, according to Charles St. Martin, a DOT spokesman.

Bucci would rather be out in a truck anyway, experiencing the storm first-hand and seeing conditions for himself."I'm a visual learner," he says. "I like to be out in it."

Bucci may beone of the few New Englanders with a fond memory of the Blizzard of '78. He was 18 years old, working for a friend clearing snow with a payloader."I thought, 'This is pretty cool,' a teenager driving around in a payloader is pretty neat," Bucci recalls.

Indeed, Bucci has had plenty of experience. He seemed calm Wednesday morning, even as forecasters were calling forsnow to hit the region Thursday and Friday.

"I don't worry about it. I don't panic because that's not going to help the situation," he says.

Despite a recent string of storms, the winter of 2020-21 isn't anywhere close to the worst he's seen. The DOT typically works 25 to 30 storms a year, but this will be only the 10th, according to Bucci and St. Martin.

Bucci prepares with theconfidence of a man who has weathered a lot of storms.

"Things always go wrong. There'salways something that comes up," Bucci says. "If Ihaven't seen it, then someone else here would have. Wewill always find a way to figure it out and get through it."

jperry@providencejournal.com

(401) 277-7614

On Twitter: @jgregoryperry

See original here:

DOT's weather watcher relies on technology, forecasters and his own senses to read snowstorms - The Providence Journal

United Nations Secretary-General, Antnio Guterres, and World Health Organization (WHO) Director-General, Dr Tedros Adhanom Ghebreyesus, have announced that a Global Diabetes Compact will be launched on 14 April 2021 to mark the 100-year anniversary of the discovery of insulin for the treatment of diabetes. The centenary offers a window of opportunity for the global diabetes community to come together to reflect on addressing barriers to accessing insulin and associated health technology products. It is an opportune time to forge a common vision among all stakeholders to develop a multisectoral plan of action to address these barriers and ensure that no person living with diabetes goes untreated.

The WHO Department of Noncommunicable Diseases (NCD), in collaboration with the Division of Medicines and Health Products, is convening a series of biannual dialogues with the private sector to define meaningful and effective contributions to the implementation of national responses for the prevention, management and control of NCDs and the attainment of related Sustainable Development Goal (SDG) targets. The dialogues will focus on mobilizing commitments and contributions by the private sector toward national NCD responses to achieve SDG targets 3.4, 3.8 and 3b by improving access to and affordability of safe, effective and quality-assured medicines and health technology products.

Improving access to medicines and health technology products for the diagnosis, management and treatment of diabetes is multi-faceted and part of a broader challenge of ensuring access to health care. It requires a robust health system which includes good leadership and governance, adequate financing, access to information and evidence, quality service delivery, a strong health workforce, and equitable access to essential medicines and health technology products of assured quality, safety, efficacy and cost-effectiveness. Effective interventions will require enhanced collaboration and commitment for greater impact at country-level. The first dialogue in the series, which is being held on 23-24 February 2021, will focus on improving access to human insulin and associated health technology products for diabetes as part of the Global Diabetes Compact. Subsequent dialogues will focus on other NCDs, such as cardiovascular disease, cancer, lung diseases, oral health, rehabilitation, sensory impairments and disability.

This first dialogue aims to encourage inputs, commitments, and contributions from the pharmaceutical and health technology product industries to support WHOs activities to improve access to medicines and health technology products for diabetes, including for the 14 April 2021 launch of the Global Diabetes Compact.

A summary report of this meeting will be available on this website after the meeting.

Go here to see the original:

Dialogue with the private sector on medicines and technologies for diabetes care, February 2021 - World Health Organization

Kanagawa Regeneration and Cell Medical Industry Network Organizers Invite RepliCel to Participate in Foreign Company Pitch Session

VANCOUVER, BC / ACCESSWIRE / February 18, 2021 / RepliCel Life Sciences Inc. (OTC PINK:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company developing next-generation technologies in aesthetics and orthopedics, announced its President and CEO, R. Lee Buckler, will present today at the RINK Festival hosted by the Regenerative Medicine & Cell Therapy Industrialization Network of Kanagawa (RINK), Kanagawa Prefecture.

The annual event is held to strengthen connections and collaborations in the regenerative medicine industry in Japan. A link to RepliCel's presentation (English audio and Japanese text) will be posted shortly after the event. To learn more, visit https://rinkrink.jp/2021.

RepliCel is participating at the express invitation of the Canadian office of the Japan External Trade Organization (JETRO) which is one of the event sponsors along with Japan's Forum for Innovative Regenerative Medicine (FIRM), Japan's Ministry of Economy, Trade and Industry (METI), the Japan Ministry of Economy, Trade and Industry Patent Office, the Kansai Regenerative Medicine Industry Consortium (KRIC), Kyoto Institute of Advanced Technology (ASTEM), Keio University, Life Science Innovation Network Japan (LINK-J), Japan Biotech Council, Kanagawa Prefectural Industrial Technology Research Institute (KISTEC), Shonan Health Innovation Park (iPark), Quebec Government Office in Japan, and Mizuho Information Research Institute Co., Ltd.

About RepliCel's Programs in Japan

RepliCel signed its first co-development and licensing agreement with a Japanese partner in 2013 for a product currently in ongoing clinical research in Japan.

RepliCel is currently laying plans for the clinical testing and commercialization of three additional technologies in Japan. These include two cell therapies - one for skin rejuvenation and one for tendon regeneration - and a next-generation dermal injector for aesthetic treatments involving a wide variety of injectable substances including cells, PRP, toxins, fillers, enzymes, drugs, other biologics, etc.

The RepliCel cell therapy technology, which is the subject of active, ongoing partnership discussions in Japan, has already been the subject of two successfully completed consultations with Japan's Pharmaceutical and Medical Devices Agency (PMDA). Planning for clinical research studies under Japan's Act for the Safety of Regenerative Medicines (ASRM) is already underway with two well-respected clinical professors of orthopedic sports medicine and clinical dermatology. Manufacturing of the clinical product will be performed by a Japanese-owned contract manufacturer preparing now for PMDA-certification under Japan's Ministry of Health, Labour, and Welfare (MHLW) applicable guidelines. The conduct of the clinical research studies will be managed by a high-quality Japanese clinical research organization.

About RepliCel Life Sciences

RepliCel is a regenerative medicine company focused on developing cell therapies for aesthetic and orthopedic conditions affecting what the Company believes is approximately one in three people in industrialized nations, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. These conditions, often associated with aging, are caused by a deficit of healthy cells required for normal tissue healing and function. Headquartered in Canada with a base of operations in Europe, RepliCel has existing partnerships in the United States, Japan, and China.

The Company's cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. All RepliCel's cell therapy product candidates are based on RepliCel's innovative technology, utilizing cell populations isolated from a patient's healthy hair follicles. RepliCel's three cell therapy products have now been tested in over 100 patients in four countries on three continents and successfully reviewed by three different regulatory agencies.

RepliCel has also developed a proprietary injection device, RCI-02, optimized for the administration of its products and licensable for use with other dermatology applications. Certain commercial rights for RCI-02 have been licensed to YOFOTO for Greater China and a limited-term exclusive distributorship to MainPointe for the United States.

The commercial rights for RCH-01 for most of Asia have been exclusively licensed to Shiseido Company. Though the legal status of this license is currently the subject of some disagreement between the parties, Shiseido continues to finance the development of the licensed product based on RepliCel's technology in their territory. The commercial rights for RCT-01 and RCS-01 have been exclusively licensed to YOFOTO (China) Health for Greater China. YOFOTO is also committed to financing the co-development of these products in their territory.

For more information, please visit http://www.replicel.com or contact:Lee Buckler, CEO, and President604-248-8693info@replicel.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this release.

SOURCE: RepliCel Life Sciences, Inc.

View source version on accesswire.com:https://www.accesswire.com/630464/RepliCel-Presents-Its-Technology-Development-and-Commercialization-Plans-for-Japan-at-Kanagawa-Regenerative-Medicine-Industry-Conference

Read the original here:

RepliCel Presents Its Technology Development and Commercialization Plans for Japan at Kanagawa Regenerative Medicine Industry Conference - BioSpace

HALIFAX, Nova Scotia--(BUSINESS WIRE)--Emera Technologies and Halifax-based Novonix Battery Technology Solutions (Novonix) are working together to develop battery pack systems to support microgrids that will provide solar power directly to homes, and could lead to exciting future opportunities across North America.

In the fall of 2020, Emera Technologies launched BlockEnergy, the first utility-owned community microgrid platform, and partnered with Lennar homebuilders to implement the technology in a new residential community in Florida. For the past year, the Emera Technologies team has also been working with Novonix, a Halifax based battery technology company, to develop a battery pack including innovative designs, custom manufacturing, and control systems to support the direct current BlockEnergy microgrid.

Emeras BlockEnergy platform is a great example of applying our technology to real life projects and developing systems with specifications not available currently in commercial products, and that have tangible downstream applications, said Dr. Chris Burns, co-founder and CEO of Novonix. This project brings the opportunity to partner on not only the development but also manufacturing of new battery systems with significant market opportunities. The target market is not limited to the United States but will also include a focus on opportunities and customers here in Canada, said Dr. Burns.

Novonix was born out of work by Dr. Jeff Dahns Research Group at Dalhousie University that focuses on lithium-ion battery research and currently works exclusively with Tesla. Dr. Dahn will join Novonix on July 1, 2021 as their Chief Scientific Advisor. Partnerships like Novonix and Emera Technologies help take battery technology advancements to the real world, in this case powering individual residential homes, said Dr. Dahn.

Emera Technologies and Novonix plan to field test the first demo units in 2021 which will help inform final decisions around system specifics and design.

Were really excited about this partnership and this project, said Rob Bennett, President and CEO of Emera Technologies. Were developing something that doesnt exist today, that will help provide people with cleaner, more reliable energy, and were able to capitalize on expertise at home in Nova Scotia to do that.

About Emera Technologies

Emera Technologies is a dedicated and nimble organization that's focused on developing new ways to deliver renewable energy to customers. Headquartered in Tampa, Florida, the team engages experts, research organizations and technology leaders to capitalize on the disruptive challenges and innovation opportunities in todays energy industry.

About Novonix

Novonix was started in Halifax, Nova Scotia in 2013 from work in Dr. Jeff Dahns group, with the goal of bringing state-of-the-art battery testing equipment from the research lab to market success. Over the past eight years, Novonix gained worldwide recognition, providing battery testing equipment and services to customers in more than 14 countries. Novonix has continually expanded, both in staff and in infrastructure and is located in Bedford, Nova Scotia. Novonix is a wholly owned subsidiary of Novonix Ltd (ASX: NVX, OTCQX: NVNXF).

See the rest here:

Emera Technologies and Novonix Partner on Innovative Battery Technology - Business Wire

Apple is researching how to embed sensors into display panels, potentially enabling both Touch ID, and Face ID without a notch.

Many of Apple's recently revealed patents and patent applications, have been concerned with making more use of necessary components. That's included a battery that doubles as a haptic feedback engine, and embedding Wi-Fi antennas in screens. Now Apple appears to be looking at just how much else can be included within an Apple Watch, or iPhone display.

"Photodetectors Integrated into Thin-Film Transistor Backplanes," is concerned with a TFT screen. Even as a display presents images, it can be simultaneously include sensors that detect a range of environments.

"An array of photodetectors may be variously configured as a biometric sensor, camera, or depth sensor, for example," says the patent application, "and may be used to generate an image (a 2D image), a depth map (a 3D image), or a video clip (a sequence of 2D or 3D images)."

These are all functions that sensors can currently do, but Apple is focusing on getting more from these sensors and do so in newer forms. That does include less expensive forms, but also thinner ones.

"Given the wide range of sensor applications, any new development in the configuration or operation of a system including a sensor can be useful," says Apple.

"New developments that may be particularly useful are developments that reduce the cost, size, complexity, part count, or manufacture time of the sensor or sensor system," it continues, "or developments that improve the sensitivity or speed of sensor or sensor system operation."

Apple's proposal is to either embed photodetectors within a TFT screen, or alongside one. These sensors may "be positioned behind a display," or "be attached to the display."

Most of the patent application, though, is concerned with how such a photodetector can be included within the display. It would "be attached to the multi-layer structure," and include "an organic photosensitive material."

Ultimately, what this means is that the screen you look at can be looking right back at you. And doing so without adding appreciably to the thickness of the screen or the device.

Photodetectors register light, so it's conceivable and the patent application mentions this that such an embedded one could be an actual camera. More specifically, it could be a Face ID camera.

Detail from the patent application showing the idea of multiple layers within a display

"[The] the array of photodetectors... may be configured to operate as a front-facing camera, a bio-authentication sensor, or a facial recognition sensor," says Apple. It may do this "alone or in combination with other sensors."

So such a display, with such sensors embedded within it, may be equally able to be used as either Face ID or under-the-screen Touch ID.

This patent application is credited to six inventors. One of whom, Jiun-Jye Chang, previously worked on a patent for a touch panel with photodetectors.

More:

New Apple technology could lead to in-screen Face ID, no notch - AppleInsider

New York, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Anti-Counterfeit Pharmaceuticals & Cosmetics Packaging Market Research Report by Technology, by End User - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p06025417/?utm_source=GNW

Market Statistics:The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.

1. The Global Anti-Counterfeit Pharmaceuticals & Cosmetics Packaging Market is expected to grow from USD 46,648.52 Million in 2020 to USD 94,394.84 Million by the end of 2025.2. The Global Anti-Counterfeit Pharmaceuticals & Cosmetics Packaging Market is expected to grow from EUR 40,902.30 Million in 2020 to EUR 82,767.18 Million by the end of 2025.3. The Global Anti-Counterfeit Pharmaceuticals & Cosmetics Packaging Market is expected to grow from GBP 36,362.24 Million in 2020 to GBP 73,580.21 Million by the end of 2025.4. The Global Anti-Counterfeit Pharmaceuticals & Cosmetics Packaging Market is expected to grow from JPY 4,978,579.15 Million in 2020 to JPY 10,074,321.39 Million by the end of 2025.5. The Global Anti-Counterfeit Pharmaceuticals & Cosmetics Packaging Market is expected to grow from AUD 67,739.85 Million in 2020 to AUD 137,073.86 Million by the end of 2025.

Market Segmentation & Coverage:This research report categorizes the Anti-Counterfeit Pharmaceuticals & Cosmetics Packaging to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Technology, the Anti-Counterfeit Pharmaceuticals & Cosmetics Packaging Market studied across Barcodes, Forensic Markers, Holograms, Overt, Covert, & Forensic Features, RfId, Serialization/Track & Trace Technologies, Tammass Encoding, and Tamper-Evident Technology. The Barcodes further studied across Digital Mass Encryption and Digital Mass Serialization.

Based on End User, the Anti-Counterfeit Pharmaceuticals & Cosmetics Packaging Market studied across Apparel & Footwear, Automotive, Cosmetics & Personal Care, Electrical & Electronics, Food & Beverage, Luxury Goods, and Pharmaceutical.

Based on Geography, the Anti-Counterfeit Pharmaceuticals & Cosmetics Packaging Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Anti-Counterfeit Pharmaceuticals & Cosmetics Packaging Market including 3M Company, Abbey Labels, Alien Technology Corp., Alpvision SA, Ampacet Corporation, Applied DNA Sciences, Arjo Solutions, ATL Security Label Systems, Authentix Inc., Avery Dennison Corp., Bayer AG, CCL Industries Inc., CFC International, Inc, Datamax-ONeil Corporation, Digimarc Corporation, DuPont de Nemours, Inc., Flint Group Corp., Impinj Inc., Inksure Technologies Inc., Intelligent Label Solutions, Label Makers Pty Ltd., OpSec Security Inc., PharmaSecure, Sicpa Holding S.A., Uflex Limited, and Zebra Technologies Corporation.

Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Anti-Counterfeit Pharmaceuticals & Cosmetics Packaging Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:1. What is the market size and forecast of the Global Anti-Counterfeit Pharmaceuticals & Cosmetics Packaging Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Anti-Counterfeit Pharmaceuticals & Cosmetics Packaging Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Anti-Counterfeit Pharmaceuticals & Cosmetics Packaging Market?4. What is the competitive strategic window for opportunities in the Global Anti-Counterfeit Pharmaceuticals & Cosmetics Packaging Market?5. What are the technology trends and regulatory frameworks in the Global Anti-Counterfeit Pharmaceuticals & Cosmetics Packaging Market?6. What are the modes and strategic moves considered suitable for entering the Global Anti-Counterfeit Pharmaceuticals & Cosmetics Packaging Market?Read the full report: https://www.reportlinker.com/p06025417/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

More:

Anti-Counterfeit Pharmaceuticals & Cosmetics Packaging Market Research Report by Technology, by End User - Global Forecast to 2025 - Cumulative...

HOWELL, N.J., Feb. 18, 2021 /PRNewswire/ -- Greenland Technologies Holding Corporation (NASDAQ: GTEC) ("Greenland"), a technology developer and manufacturer of electric industrial vehicles and drivetrain systems for material handling machineries and vehicles, and Fujian South China Heavy Machinery Manufacture Co. Ltd. ("SOCMA", http://www.socmachinery.com), a leading company specialized in designing, manufacturing and distributing heavy industrial machinery and vehicles, today announced a co-operation agreement to utilize SOCMA's existing supply-chain and certain technologies to support Greenland's production of electric industrial vehicles in the United States. The agreement also represents a commitment by Greenland to invest in the U.S. as a key center of innovation in the global electric vehicle market.

Under the agreement, both parties intend to establish a strategic partnership to fully cooperate on technology sharing and supply chain management for the production of electric industrial vehicles in the U.S. SOCMA has agreed to provide and supply to GTEC the materials, parts and components, and related supply chain required for the development and manufacture of electric industrial vehicles in the U.S. SOCMA agrees that GTEC shall use the relevant SOCMA technologies and patents involved in GTEC's procurement of engineering vehicle parts and materials from SOCMA free of charge GTEC will capitalize on its global business development and technology development capabilities to accelerate the launch of its electric industrial vehicles globally with support from SOCMA.

Raymond Wang, CEO of Greenland, commented, "We are excited to partner with SOCMA, a proven leader in the manufacture of heavy machinery, and see this as a positive development, which will ensure the utilization of SOCMA's existing supply-chain for GTEC's U.S. production of its electric industrial vehicles. This cooperation agreement was designed to leverage both companies' expertise, best practices and vast proprietary knowledge for our mutual benefit, and enhancement of our respective competitive positions."

Story continues

"For GTEC, this cooperation will accelerate our electric industrial vehicle production in the United States. We believe the competitive advantage we will gain by now having access to SOCMA's supply chain, technologies and patents is invaluable. Today's announcement is a first but very important step. We look forward to sharing additional details as we progress, with initial production of our own electric, GTEC's first industrial vehicle, integrating our own components, targeted between 3Q 2021 and 4Q 2021. We plan to focus on the 1.8 ton electric load vehicle segment, given the addressable market size and favorable competitive environment. We believe this will significantly expand GTEC's long-term growth prospects and ability to build shareholder value."

About Greenland Technologies Holding Corporation

Greenland Technologies Holding Corporation (NASDAQ: GTEC) is a developer and a manufacturer of drivetrain systems for material handling machineries and electric vehicles, as well as electric industrial vehicles. For more information visit http://www.gtec-tech.com.

Forward-Looking Statements

This press release contains statements that may constitute "forward-looking statements." Such statements reflect Greenland's current views with respect to future events and are subject to such risks and uncertainties, many of which are beyond the control of Greenland, including those set forth in the Risk Factors section of Greenland's Annual Report on Form 10-K and Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission ("SEC"). Copies are available on the SEC's website, http://www.sec.gov. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, Greenland's expectations with respect to future performance. In addition, there is uncertainty about the further spread of the COVID-19 virus or the occurrence of another wave of cases and the impact it may have on the Company's operations, the demand for the Company's products, global supply chains and economic activity in general. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated or expected. Statements contained in this news release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. Greenland does not intend and does not assume any obligation to update these forward-looking statements, other than as required by law.

View original content to download multimedia:http://www.prnewswire.com/news-releases/socma-and-greenland-technologies-sign-co-operation-agreement-to-support-us-production-of-electric-industrial-vehicles-301230523.html

SOURCE Greenland Technologies Holding Corporation

Read the rest here:

SOCMA and Greenland Technologies Sign Co-Operation Agreement to Support U.S. Production of Electric Industrial Vehicles - Yahoo Finance

The Coast Guards Office of Operating and Environmental Standards has published a revised 2021 Shipboard Technology Evaluation Program (STEP) Application Package. This application facilitates the process for both prototype Ballast Water Management Systems (BWMS) and BWMS undergoing U.S. Type Approval testing under the oversight of an Independent Laboratory (IL). The application and instructions for submitting are available on the Office of Operating and Environmental Standardswebpage.

The STEP application incorporates fully validated experimental design parameters developed through the U.S. Environmental Protection Agencys Environmental Technology Verification (ETV) process, as well as ETV harmonized shipboard testing requirements. Navigation and Vessel Inspection Circular 01-04 (NVIC 01-04) establishes the process and gives additional information for vessel owners to apply to STEP.

The revised format is intended to assist applicants to prepare and submit all necessary information in a clear and consistent manner, thus facilitating the review process. Potential applicants should familiarize themselves with the guidance before completing the application. There is NO CHARGE for applying to or being enrolled in STEP.

If you have questions, please contact the Chief of the Environmental Standards Division at[emailprotected]

Read more at USCG

(Visited 10 times, 10 visits today)

More here:

Shipboard Technology Evaluation Program: Revised Application for Ballast Water Management Systems Homeland Security Today - HSToday

BEDFORD, Mass.--(BUSINESS WIRE)--Aspen Technology, Inc. (NASDAQ:AZPN), a global leader in asset optimization software, today announced that Antonio Pietri, President and Chief Executive Officer, and Karl Johnsen, Chief Financial Officer, will present at the KeyBanc Emerging Technology Virtual Summit. The presentation is scheduled for Wednesday, February 24, 2021 at 10:55 a.m. ET.

The presentation will be webcast live and available for a limited time on the Investor Relations section of the companys website at http://ir.aspentech.com/.

About AspenTech

Aspen Technology (AspenTech) is a global leader in asset optimization software. Its solutions address complex, industrial environments where it is critical to optimize the asset design, operation and maintenance lifecycle. AspenTech uniquely combines decades of process modelling expertise with artificial intelligence. Its purpose-built software platform automates knowledge work and builds sustainable competitive advantage by delivering high returns over the entire asset lifecycle. As a result, companies in capital-intensive industries can maximize uptime and push the limits of performance, running their assets safer, greener, longer and faster. Visit AspenTech.com to find out more.

2021 Aspen Technology, Inc. AspenTech and the Aspen leaf logo are trademarks of Aspen Technology, Inc.

Originally posted here:

Aspen Technology to Present at the KeyBanc Emerging Technology Summit - Business Wire

Battelle, the worlds largest independent private R&D organization, announced today that it is in discussions to provide Cascade Environmental with a patented process (International Patent US10,907,143 B2) for the use of encapsulated enzymes to remediate recalcitrant pollutants.

Cascade Environmental, a leading provider of environmental and infrastructure drilling, site characterization and environmental remediation applications, is exploring use of Battelles technology at its sites.

Battelles optimized encapsulation process yields a unique formulation of proprietary mixture of fungal-derived, oxidoreducing, time-released enzymes for rapid degradation of recalcitrant contaminants. The structure and composition of encapsulated enzyme beads are highly effective for remediation of petroleum hydrocarbons (TPHs), polychlorinated biphenyls (PCBs), and polycyclic aromatic hydrocarbons (PAHs).

When compared to invasive technologies such as excavation, in situ or ex situ application of encapsulated enzymes to soil, groundwater and sediment has multiple benefits. The encapsulated enzyme formulation, currently demonstrating two-year shelf stability, has a broad spectrum of treatment and provides a controlled release of enzymes to the contaminated matrix eliminating multiple application events. This technology requires minimum effort at application, generates no waste and promotes complete degradation of pollutants via enrichment of naturally abundant microorganisms as the contaminant becomes more bioavailable after enzymatic treatment.

"Were pleased to begin working with Cascade in this promising technology collaboration that will have broad industry impact," said Dan Longbrake, Commercial Business Director for PFAS and Environmental Restoration. "We expect to be able to release more information as we finalize details."

Co-inventors of the process are Battelle researchers Kate Kucharzyk, Tony Duong and former Battelle researcher Ram Lalgudi.

Story continues

"Adding a slow-release enzymatic chemistry solution to the new Cascade Chemistries line of products deepens our capabilities to support our clients at their challenging TPH, PCB and PAH-impacted sites," said Scott Wisher, Senior Vice President at Cascade. "We envision these chemistries being appropriate for in situ injection along with conventional remediation including soil blending."

About Battelle

Every day, the people of Battelle apply science and technology to solving what matters most. At major technology centers and national laboratories around the world, Battelle conducts research and development, designs and manufactures products, and delivers critical services for government and commercial customers. Headquartered in Columbus, Ohio since its founding in 1929, Battelle serves the national security, health and life sciences, and energy and environmental industries. For more information, visit http://www.battelle.org.

About Cascade

Cascade is a field services contractor that partners with our clients to provide seamless environmental and geotechnical solutions from concept to completion. Our vision is to integrate technology, safety, sustainability, and human potential to tackle the challenging environmental and geotechnical issues facing our clients. For more information on Cascade, please visit http://www.cascade-env.com.

For more information on the new injection chemistries and integrated turnkey remediation services, contact Eliot Cooper, Vice President of Technology at ecooper@cascade-env.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005758/en/

Contacts

Katy Delaney(614) 424-7208delaneyk@battelle.org

T.R. Massey(614) 424-5544masseytr@battelle.org

Read the original here:

Cascade and Battelle Collaborate to Apply Patented Environmental Remediation Technology for Recalcitrant Contaminants - Yahoo Finance